Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189229 | 1.00 | EP300 (0.46) | EP300ACE2GPR84FFAR1MAPT | |
| SCHEMBL20187390 | 1.00 | EP300 (0.46) | EP300ACE2GPR84FFAR1MAPT | |
| SCHEMBL28579233 | 0.91 | EP300 (0.50) | EP300ACE2GPR84FFAR1MAPT | |
| SCHEMBL10743747 | 0.85 | CHRM1 (0.37) | EP300 | |
| SCHEMBL22092203 | 0.83 | EP300 (0.44) | EP300ACE2GPR84FFAR1CA1 | |
| SCHEMBL15791893 | 0.82 | LCK (0.48) | EP300ACE2GPR84FFAR1MAPT | |
| SCHEMBL16059073 | 0.82 | LCK (0.48) | EP300ACE2GPR84FFAR1MAPT | |
| SCHEMBL16059072 | 0.82 | LCK (0.48) | EP300ACE2GPR84FFAR1MAPT | |
| SCHEMBL10386188 | 0.82 | LCK (0.48) | EP300ACE2GPR84FFAR1MAPT | |
| SCHEMBL2798260 | 0.82 | LCK (0.48) | EP300ACE2GPR84FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539261-B2 | Encapsulated compositions | GIVAUDAN SA (CH) | 2026-02-03 | — | — | US | disclosed |
| US-20250099347-A1 | ENCAPSULATED COMPOSITIONS | GIVAUDAN SA (CH) | 2025-03-27 | — | — | US | disclosed |
| US-20240206461-A1 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | ENCAPSYS, LLC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4370644-A1 | CONSUMER PRODUCTS COMPRISING DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | The Procter & Gamble Company (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4369931-A2 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | Encapsys, LLC (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117396071-A | Delivery particles with high core to wall ratio | 恩盖普有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4251723-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230056295-A1 | CONSUMER PRODUCTS COMPRISING DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | THE PROCTER & GAMBLE COMPANY | 2023-02-23 | — | — | US | disclosed |
| WO-2023287867-A2 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | ENCAPSYS, LLC (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288239-A1 | CONSUMER PRODUCTS COMPRISING DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | THE PROCTER & GAMBLE COMPANY (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-4119646-A1 | CONSUMER PRODUCTS COMPRISING DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | The Procter & Gamble Company (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-114727924-A | Pro-fragrance compositions | 弗门尼舍有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022112202-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3898912-A1 | A METHOD OF COUNTERING MALODOUR IN A WASHING MACHINE COMPRISING THE ADDITION OF A FRAGRANCE PRECURSOR | Givaudan SA (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113195697-A | Perfuming method | 奇华顿股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020125922-A1 | A METHOD OF COUNTERING MALODOUR IN A WASHING MACHINE COMPRISING THE ADDITION OF A FRAGRANCE PRECURSOR | GIVAUDAN SA (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-3544950-A1 | PRECURSOR COMPOUNDS FOR FRAGRANT ALDEHYDES | Givaudan S.A. (CH) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018096176-A1 | PRECURSOR COMPOUNDS FOR FRAGRANT ALDEHYDES | GIVAUDAN SA (CH) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240206461-A1 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | CETP, CHMP4B, HDLBP | EP300 1459/4885ACE2 1588/4885GPR84 3159/4885 |
| US-12539261-B2 | Encapsulated compositions | ALG1, GNE, ILK | EP300 179/4885ACE2 2631/4885GPR84 633/4885 |
| US-20250099347-A1 | ENCAPSULATED COMPOSITIONS | AHCYL1, BHMT2, EPHX2 | EP300 1235/4885ACE2 3443/4885GPR84 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.